Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 1
1972 1
1974 1
1975 1
1982 2
1983 3
1984 3
1985 7
1986 6
1987 1
1988 4
1989 2
1990 4
1991 2
1992 2
1993 3
1994 4
1995 5
1996 12
1997 2
1998 5
1999 4
2000 2
2001 5
2002 5
2003 8
2004 8
2005 9
2006 6
2007 5
2008 10
2009 8
2010 10
2011 7
2012 13
2013 8
2014 5
2015 11
2016 12
2017 15
2018 12
2019 3
2020 11
2021 24
Text availability
Article attribute
Article type
Publication date

Search Results

250 results
Results by year
Filters applied: . Clear all
Page 1
Novel therapeutics in myeloproliferative neoplasms.
Venugopal S, Mascarenhas J. Venugopal S, et al. J Hematol Oncol. 2020 Dec 2;13(1):162. doi: 10.1186/s13045-020-00995-y. J Hematol Oncol. 2020. PMID: 33267911 Free PMC article. Review.
Therefore, the management strategies focus on thrombosis risk mitigation in PV/ET, alleviation of symptom burden and improvement in cytopenias and red blood cell transfusion requirements, and disease course alteration in PMF. The United States Food and Drug Administ …
Therefore, the management strategies focus on thrombosis risk mitigation in PV/ET, alleviation of symptom burden and improvement in cytopeni …
Pathobiology of secondary immune thrombocytopenia.
Cines DB, Liebman H, Stasi R. Cines DB, et al. Semin Hematol. 2009 Jan;46(1 Suppl 2):S2-14. doi: 10.1053/j.seminhematol.2008.12.005. Semin Hematol. 2009. PMID: 19245930 Free PMC article. Review.
Sudden and severe onset of thrombocytopenia has been observed in children after vaccination for measles, mumps, and rubella or natural viral infections, including Epstein-Barr virus, cytomegalovirus, and varicella zoster virus. ...
Sudden and severe onset of thrombocytopenia has been observed in children after vaccination for measles, mumps, and rubella or natura …
The ITP syndrome: pathogenic and clinical diversity.
Cines DB, Bussel JB, Liebman HA, Luning Prak ET. Cines DB, et al. Blood. 2009 Jun 25;113(26):6511-21. doi: 10.1182/blood-2009-01-129155. Epub 2009 Apr 24. Blood. 2009. PMID: 19395674 Free PMC article. Review.
Effects of Thermomechanical Stimulation during Vaccination on Anxiety, Pain, and Satisfaction in Pediatric Patients: A Randomized Controlled Trial.
Redfern RE, Chen JT, Sibrel S. Redfern RE, et al. J Pediatr Nurs. 2018 Jan-Feb;38:1-7. doi: 10.1016/j.pedn.2017.09.009. Epub 2017 Sep 28. J Pediatr Nurs. 2018. PMID: 29167074 Clinical Trial.
PURPOSE: Vaccination can be a significant source of pain for pediatric patients, which could result in fear of medical procedures and future reluctance to seek medical care. ...PRACTICE IMPLICATIONS: The Buzzy device is an easy to implement intervention to reduce pediatric …
PURPOSE: Vaccination can be a significant source of pain for pediatric patients, which could result in fear of medical procedures and …
Congenital rubella.
Dudgeon JA. Dudgeon JA. J Pediatr. 1975 Dec;87(6 Pt 2):1078-86. doi: 10.1016/s0022-3476(75)80119-3. J Pediatr. 1975. PMID: 1102644 Review.
The need for preventive measures is discussed in relation to the total number of children damaged annually and the importance of multiple defects leading to severe handicaps. Active immunization procedures to prevent congenital rubella defects are reviewed, with comments o …
The need for preventive measures is discussed in relation to the total number of children damaged annually and the importance of multiple de …
Acquired inhibitors.
Cohen AJ, Kessler CM. Cohen AJ, et al. Baillieres Clin Haematol. 1996 Jun;9(2):331-54. doi: 10.1016/s0950-3536(96)80067-9. Baillieres Clin Haematol. 1996. PMID: 8800509 Review.
Lentiviral haemopoietic stem/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1/2 clinical study.
Ferrua F, Cicalese MP, Galimberti S, Giannelli S, Dionisio F, Barzaghi F, Migliavacca M, Bernardo ME, Calbi V, Assanelli AA, Facchini M, Fossati C, Albertazzi E, Scaramuzza S, Brigida I, Scala S, Basso-Ricci L, Pajno R, Casiraghi M, Canarutto D, Salerio FA, Albert MH, Bartoli A, Wolf HM, Fiori R, Silvani P, Gattillo S, Villa A, Biasco L, Dott C, Culme-Seymour EJ, van Rossem K, Atkinson G, Valsecchi MG, Roncarolo MG, Ciceri F, Naldini L, Aiuti A. Ferrua F, et al. Lancet Haematol. 2019 May;6(5):e239-e253. doi: 10.1016/S2352-3026(19)30021-3. Epub 2019 Apr 10. Lancet Haematol. 2019. PMID: 30981783 Free PMC article. Clinical Trial.
The primary efficacy endpoints were overall survival, sustained engraftment of genetically corrected HSPCs, expression of vector-derived WASP, improved T-cell function, antigen-specific responses to vaccinations, and improved platelet count and mean platelet volume normali …
The primary efficacy endpoints were overall survival, sustained engraftment of genetically corrected HSPCs, expression of vector-derived WAS …
Engineering less immunogenic and antigenic FVIII proteins.
Pratt KP. Pratt KP. Cell Immunol. 2016 Mar;301:12-7. doi: 10.1016/j.cellimm.2015.10.008. Epub 2015 Nov 2. Cell Immunol. 2016. PMID: 26566286 Free PMC article. Review.
Inhibitors develop in up to one of every three patients, yet remarkably, a substantial majority of severe hemophilia A patients, who circulate no detectable FVIII antigen or activity, acquire immune tolerance to FVIII during initial infusions or else after intensive FVIII …
Inhibitors develop in up to one of every three patients, yet remarkably, a substantial majority of severe hemophilia A patients, who …
250 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page